{"product_id":"teva-pestle-analysis","title":"(TEVA) Teva Pharmaceutical Industries Limited PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Teva Pharmaceutical Industries Limited PESTLE Analysis explains the political, economic, social, technological, legal, and environmental forces shaping Teva and why that matters for strategy, investment, and risk management. This page shows a real preview\/sample of the report so you can judge style and depth; purchase the full version to receive the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS and EU price controls\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUS and EU price controls directly shape Teva Pharmaceutical Industries Limited’s sales because reimbursement decides access for its generics and specialty drugs. In the US, the Inflation Reduction Act’s first 10 Medicare drug prices take effect in 2026, while Europe’s tender and reference-pricing systems can shift volume fast. For Teva Pharmaceutical Industries Limited, even a small formulary loss can move large generic volumes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIsrael headquarters exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited is headquartered in Tel Aviv-Yafo, Israel, and its 2025 global footprint makes it sensitive to local shocks. Regional instability can disrupt freight, staffing, and site access, while also weighing on sentiment for a company that reported about 37,000 employees worldwide. Geopolitical risk stays part of the operating profile, so even short conflicts can affect supply continuity and valuation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade and sanctions risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited depends on cross-border APIs, manufacturing, and distribution, so trade barriers can hit fast. In 2024, Teva posted $16.5 billion in revenue, and with sales across many markets, even small customs delays or sanctions can disrupt supply. Higher tariffs also raise input costs and can squeeze margins on generic drugs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePublic healthcare procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited depends heavily on public and semi-public buyers, especially for generic medicines, so government tenders can quickly shape volume and pricing. These contracts are often large but concentrated, which raises revenue visibility when won and creates sharp downside when lost. In 2025, this matters more as public payers keep pushing lower unit prices and tighter award terms.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge public buyer exposure\u003c\/li\u003e\n\u003cli\u003eTender wins drive volume\u003c\/li\u003e\n\u003cli\u003eLosses hit revenue visibility\u003c\/li\u003e\n\u003cli\u003ePrice pressure stays high\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePolicy focus on affordable medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolicy still favors affordable medicines: in the U.S., generic drugs were 90% of prescriptions but only 13.1% of drug spending in 2023, so governments keep using them to cut health costs. That supports Teva Pharmaceutical Industries Limited’s core generics business, but it also keeps prices tight and margins pressured. Specialty products face much closer budget and reimbursement review.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGenerics stay politically preferred\u003c\/li\u003e\n\u003cli\u003ePricing pressure stays high\u003c\/li\u003e\n\u003cli\u003eSpecialty drugs face stricter review\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTeva Faces Rising Drug-Price Pressure and Geopolitical Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited faces heavy political risk from drug-price control and public payer pressure in the US and Europe. The IRA’s first Medicare price cuts start in 2026, while EU tender and reference-pricing systems keep generics under tight pricing. Teva Pharmaceutical Industries Limited also stays exposed to Israel-linked geopolitical shocks and cross-border trade rules.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003cth\u003eTeva impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS IRA\u003c\/td\u003e\n\u003ctd\u003e10 drugs in 2026\u003c\/td\u003e\n\u003ctd\u003eMore price pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS generics mix\u003c\/td\u003e\n\u003ctd\u003e90% Rx, 13.1% spend\u003c\/td\u003e\n\u003ctd\u003eLow-price policy bias\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal scale\u003c\/td\u003e\n\u003ctd\u003eAbout 37,000 employees\u003c\/td\u003e\n\u003ctd\u003eHigher geopolitical exposure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eExplores how political, economic, social, technological, environmental, and legal forces shape Teva Pharmaceutical Industries Limited’s risks and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise Teva PESTLE summary that quickly highlights external risks and opportunities for easier planning and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eConsolidates primary industry reports, regulatory filings, and peer benchmarks to speed validation of Teva’s market sizing, pricing, and competitive assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric price erosion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGeneric price erosion is a constant risk for Teva Pharmaceutical Industries Limited because many producers can enter fast after launch, pushing prices down sharply. In the U.S. generic market, a product often loses most of its value within months as more suppliers arrive, so Teva’s margins depend heavily on product mix and scale. That pressure is clear in Teva’s 2024 revenue of about $16.5 billion, where low-priced generics still shape profit quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation and interest rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInflation still matters because higher costs for raw materials, freight, and labor can squeeze Teva Pharmaceutical Industries Limited's margins; Teva also reported about $17 billion of debt, so interest costs stay a real burden. \u003c\/p\u003e\n\u003cp\u003eWith rates still high by recent standards, refinancing or carrying that debt can drain cash that could go to R\u0026amp;D or launches. \u003c\/p\u003e\n\u003cp\u003eSo cost discipline in plants, supply chains, and headcount remains economically critical. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eForeign exchange volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited sells and pays costs in U.S. dollars, euros, and other currencies, so foreign exchange swings can move reported results fast. In 2024, Teva posted about $16.5 billion in revenue, so even a 1% currency shift can change reported sales by roughly $165 million. That makes earnings more volatile even when demand stays steady.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHealthcare spending pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn 2026, health systems stay budget-tight, so payers keep favoring lower-cost generics and pushing back on premium pricing. For Teva Pharmaceutical Industries Limited, that supports volume in off-patent medicines but limits specialty price growth, since reimbursement reviews can slow uptake. Generic drugs can cost 80% less than brands, which keeps demand strong when budgets are tight.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGenerics gain when budgets tighten\u003c\/li\u003e\n\u003cli\u003eSpecialty pricing faces payer pushback\u003c\/li\u003e\n\u003cli\u003eReimbursement delays slow adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePortfolio mix recovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited’s portfolio mix is improving as CNS, respiratory, and oncology products add more balance to a still-generic-heavy base. AUSTEDO topped $2.0 billion in 2024 sales, while AJOVY and Copaxone still matter for cash flow, helping offset price pressure in older generics if demand holds.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher-value brands lift mix\u003c\/li\u003e\n\u003cli\u003eAUSTEDO is a key growth engine\u003c\/li\u003e\n\u003cli\u003eAJOVY supports migraine revenue\u003c\/li\u003e\n\u003cli\u003eCopaxone still aids cash generation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTeva’s Growth Is Squeezed by Pricing, Debt, and FX\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited faces constant generic price erosion, so revenue quality depends on scale and mix; 2024 sales were about $16.5 billion. Inflation and about $17 billion of debt also keep costs and interest expense high, which limits cash for launches and R\u0026amp;D.\u003c\/p\u003e\n\u003cp\u003eCurrency swings can move results fast because Teva sells in dollars, euros, and other currencies.\u003c\/p\u003e\n\u003cp\u003eBudget-tight health systems still favor lower-cost generics, but they also push back on specialty pricing and reimbursement.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eEconomic factor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue base\u003c\/td\u003e\n\u003ctd\u003eAbout $16.5B in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt load\u003c\/td\u003e\n\u003ctd\u003eAbout $17B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX exposure\u003c\/td\u003e\n\u003ctd\u003e1% move ≈ $165M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDemand mix\u003c\/td\u003e\n\u003ctd\u003eGenerics gain in tight budgets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eTeva Pharmaceutical Industries Limited PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact PESTLE analysis of Teva Pharmaceutical Industries Limited you’ll receive after purchase—fully formatted and ready to use. This file includes Political, Economic, Social, Technological, Legal, and Environmental factors as presented. No placeholders or teasers—what you see is the final, download-ready document. The content and structure match the delivered product exactly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAging populations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAging populations are lifting demand for chronic-disease drugs: the UN says 1 in 6 people worldwide will be 60+ by 2030, up from 1 in 11 in 2019. That trend supports Teva Pharmaceutical Industries Limited’s focus on CNS, pain, respiratory, and oncology, where older patients need long-term treatment. More years on therapy also means higher prescription volume and steadier refill demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChronic disease burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChronic disease burden supports steady demand for Teva Pharmaceutical Industries Limited. Asthma affects about 262 million people, COPD about 392 million, and migraine roughly 1.1 billion worldwide, so these therapies need repeat use. Cancer added an estimated 20 million new cases in 2022, which also lifts demand for supportive care across regions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAffordability preference\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients and health systems keep choosing lower-cost medicines, and in the US generics filled about 90% of prescriptions while taking just 18% of drug spending. That price gap makes affordability a social norm, not a niche preference. Teva Pharmaceutical Industries Limited benefits because its large generic base matches this demand for cheaper access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTreatment adherence and convenience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eConvenience is a real driver of treatment adherence: WHO says about 50% of patients with chronic disease do not take medicines as prescribed. Teva’s Digihaler range meets that need with device-based dosing and built-in sensing, making inhaler use simpler in daily life.\u003c\/p\u003e\n\u003cp\u003eSimpler devices and fewer steps can improve real-world use, especially in long-term therapy where routine matters more than lab efficacy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuilt-in sensing supports easier inhaler use\u003c\/li\u003e\n\u003cli\u003eSimplified dosing can lift adherence\u003c\/li\u003e\n\u003cli\u003eConvenience matters in chronic care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMental health awareness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMental health awareness is lifting diagnosis and treatment rates for schizophrenia, migraine, and movement disorders, and that directly helps Teva Pharmaceutical Industries Limited. WHO says migraine affects about 1 billion people worldwide, while schizophrenia affects about 24 million, so Teva’s CNS brands AUSTEDO and AJOVY sit in large, better-recognized markets.\u003c\/p\u003e\n\u003cp\u003eMore public discussion also pushes earlier care and better follow-up, which supports prescription volume. Long-acting injectable formats can close adherence gaps, and that matters because missed doses still weaken outcomes in chronic CNS care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAwareness expands diagnosis and treatment uptake.\u003c\/li\u003e\n\u003cli\u003eAUSTEDO and AJOVY match CNS demand.\u003c\/li\u003e\n\u003cli\u003eLong-acting formats can improve adherence.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTeva Gains as Aging, Nonadherence, and Generic Cost Pressure Rise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited benefits from aging, chronic illness, and cost pressure: the UN says 1 in 6 people will be 60+ by 2030, WHO says 50% of chronic patients miss doses, and US generics fill about 90% of prescriptions but only 18% of drug spend. That supports Teva's low-cost and adherence-focused portfolio.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAging\u003c\/td\u003e\n\u003ctd\u003e1 in 6 aged 60+ by 2030\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence\u003c\/td\u003e\n\u003ctd\u003e50% miss doses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics\u003c\/td\u003e\n\u003ctd\u003e90% scripts, 18% spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplex dosage forms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited makes 8 dosage forms: tablets, capsules, injectables, inhalables, liquids, patches, ointments, and creams. It also runs sterile, hormone, potent, and cytotoxic products, so advanced process control and containment are vital. That mix raises GMP pressure and makes quality failures costly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigihaler inhaler platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva’s Digihaler platform includes 2 connected inhalers, ProAir Digihaler and AirDuo Digihaler, that track each actuation and inhalation metric through onboard sensors. The data can support digital monitoring and adherence checks, linking drug delivery with tech-based coaching. This matters in asthma and COPD care, where missed doses and poor technique still drive avoidable worsening.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-acting injectable pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited is working with MedinCell on long-acting injectable drugs, including a risperidone program for schizophrenia. Long-acting delivery can cut dosing from daily pills to monthly or longer intervals, which helps persistence in a condition where nonadherence can exceed 40%. That matters for Teva’s pipeline because better convenience can support uptake and reduce relapse risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAPI manufacturing capability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited makes many active pharmaceutical ingredients in-house, which helps keep supply steadier and gives tighter quality control. In 2024, Teva reported net sales of about $16.5 billion, so this vertical integration matters at scale. It also cuts dependence on third-party API suppliers, which can lower disruption risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIn-house API production supports continuity.\u003c\/li\u003e\n\u003cli\u003eQuality oversight stays under Teva.\u003c\/li\u003e\n\u003cli\u003eLess reliance on outside suppliers.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialty and biologic know-how\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited runs a mix of generics, specialty drugs, and biopharmaceutical products, so it needs different R\u0026amp;D, data, and plant systems for each line. Complex products like biosimilars and specialty therapies depend more on process control, analytics, and tech-heavy quality checks than simple generics. That makes manufacturing know-how a real edge, not just a support function.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDifferent products need different tech stacks.\u003c\/li\u003e\n\u003cli\u003eBiologic output depends on precise process control.\u003c\/li\u003e\n\u003cli\u003eTech capability supports differentiated medicines.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTeva’s Tech Edge: Connected Inhalers and Complex Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited’s technology edge rests on connected devices, complex manufacturing, and in-house API production. Its Digihaler platform uses onboard sensors to track inhaler use, while long-acting injectables and sterile, hormone, potent, and cytotoxic lines demand tighter process control. In 2024, net sales were about $16.5 billion, so plant and data systems matter at scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTech factor\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigihaler\u003c\/td\u003e\n\u003ctd\u003e2 connected inhalers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003eAbout $16.5 billion, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDosage forms\u003c\/td\u003e\n\u003ctd\u003e8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA and EMA GMP compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited’s global plants must pass FDA and EMA GMP checks, especially for sterile and injectable drugs. GMP failures can trigger warning letters, batch holds, and slower approvals, which can cut output and delay launches. For a high-volume maker like Teva, even one inspection gap can hit supply and margins fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent and exclusivity disputes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatent and exclusivity disputes are a core risk for Teva Pharmaceutical Industries Limited because generic and specialty drugs can lose revenue fast when courts or regulators shift launch timing. In Teva Pharmaceutical Industries Limited’s 2024 results, revenue was about $16.5 billion, with AUSTEDO sales near $1.9 billion, so even a short delay or early generic entry can move cash flow. Legal wins or losses can change product value by hundreds of millions of dollars.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOpioid settlement legacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited still carries the legal overhang of US opioid litigation. In 2022, it agreed to a settlement framework worth up to $4.25 billion over 13 years, including cash and medicine supply. That deal made the opioid issue a lasting financial and reputational reference point for the Company.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAnti-corruption and sanctions rules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited’s global footprint raises anti-bribery and sanctions risk across sales, exports, distributors, and public-sector deals. In 2024, Teva reported about $16.5 billion in revenue, so even small compliance failures can hit a large base through fines, license limits, or lost market access. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal reach lifts corruption exposure\u003c\/li\u003e\n\u003cli\u003ePublic tenders need tight controls\u003c\/li\u003e\n\u003cli\u003eSanctions breaches can cut exports\u003c\/li\u003e\n\u003cli\u003ePenalties can restrict operations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePrivacy and clinical compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited’s digital products and clinical studies create strict data-protection duties, especially for patient and trial records. Under GDPR, a serious breach can trigger fines up to 4% of global annual turnover, and delayed controls can also damage trust with regulators, doctors, and trial sites.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatient data needs privacy-by-design controls.\u003c\/li\u003e\n\u003cli\u003eTrial data must follow local privacy laws.\u003c\/li\u003e\n\u003cli\u003eCompliance lapses raise fine and trust risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTeva Faces Legal Risks That Could Hit Revenue, Cash, and Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited faces legal pressure from FDA and EMA GMP rules, patent fights, opioid claims, and privacy laws, so compliance risk can move revenue and cash fast. In 2024, revenue was about $16.5 billion and AUSTEDO sales were near $1.9 billion, so launch delays or injunctions can matter a lot. The opioid settlement still stands at up to $4.25 billion over 13 years. GDPR breaches can also bring fines up to 4% of global turnover.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal factor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue base\u003c\/td\u003e\n\u003ctd\u003e$16.5B in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAUSTEDO sales\u003c\/td\u003e\n\u003ctd\u003e~$1.9B in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpioid settlement\u003c\/td\u003e\n\u003ctd\u003eUp to $4.25B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGDPR penalty\u003c\/td\u003e\n\u003ctd\u003eUp to 4% of turnover\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnergy and water intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePharmaceutical plants use a lot of power and water, and sterile and API lines are the most resource heavy. For Teva Pharmaceutical Industries Limited, even small efficiency gains can cut utility costs and lower emissions, which matters in a business that runs on thin margins. In 2025, energy and water use stay a key PESTLE risk because they hit both cost and compliance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHazardous waste management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited handles potent, cytotoxic, and hormone-related materials, so hazardous waste segregation, sealed storage, and controlled disposal are core site-safety needs. WHO says about 15% of healthcare waste is hazardous, and U.S. EPA rules treat 1,000 kg a month or more as a large quantity generator, so compliance risk is real. Strong containment also lowers spill, worker-exposure, and permit-risk costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmissions and climate disclosure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal drug makers face tougher greenhouse-gas reporting, and Teva Pharmaceutical Industries Limited is no exception. Its climate disclosures cover a wide footprint across manufacturing and supply-chain sites, so emissions data can affect investor screening, regulator checks, and customer trust.\u003c\/p\u003e\n\u003cp\u003eTeva’s latest sustainability reporting shows that climate metrics are now part of core governance, not just ESG marketing. For a company selling medicines in dozens of markets, weak disclosure can raise financing and compliance risk, while clear reporting helps keep access to capital and bids.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePackaging and medicine waste\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePharmaceutical products need heavy packaging, like blisters, vials, and cartons, to protect safety and shelf life, but that also raises plastic, paper, and medicine waste. For Teva Pharmaceutical Industries Limited, cutting packaging waste matters because it lowers disposal pressure and can make shipping and warehousing simpler and cheaper.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eLess packaging cuts waste and handling.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eReusable design can improve supply-chain efficiency.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eLower material use can reduce costs and emissions.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSupply resilience to climate events\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExtreme weather can halt plants, delay shipping, and disrupt active-ingredient sourcing, so Teva Pharmaceutical Industries Limited needs backup sites, dual suppliers, and higher safety stock. Climate disruption is a 2026 operating risk because even short outages can hit output and service levels. Strong network design matters more than just low cost.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse resilient sites and routes\u003c\/li\u003e\n\u003cli\u003eKeep inventory for weather shocks\u003c\/li\u003e\n\u003cli\u003eSplit sourcing across regions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTeva’s Biggest ESG Risks: Waste, Water, and Climate Disruption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited’s biggest environmental pressures are energy, water, waste, and climate disruption. WHO says about 15% of healthcare waste is hazardous, and U.S. EPA large-quantity generator rules start at 1,000 kg a month, so disposal control is a real compliance cost. Storms and supply shocks can still stop plants and delay APIs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey risk\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHazardous waste\u003c\/td\u003e\n\u003ctd\u003e15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEPA threshold\u003c\/td\u003e\n\u003ctd\u003e1,000 kg\/month\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClimate disruption\u003c\/td\u003e\n\u003ctd\u003eSupply and plant risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235065110793,"sku":"teva-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/teva-pestle-analysis.webp?v=1785733429","url":"https:\/\/dcfanalyst.com\/products\/teva-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}